Kim, S., Kim, J. S., Kim, S. W., Brantley, E., Yun, S. J., He, J., . . . Fidler, I. J. (2011). Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer. Neoplasia Press Inc.
Styl ChicagoKim, Sun-Jin, et al. Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel By Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer. Neoplasia Press Inc, 2011.
Citace podle MLAKim, Sun-Jin, et al. Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel By Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer. Neoplasia Press Inc, 2011.